Skip to Main Content

Advertisement

Skip Nav Destination

Issues

Cancer Immunology Research

Cancer Immunology Research, launched in 2013 with Glenn Dranoff as founding Editor-in-Chief, is published by the AACR. The Journal illuminates the interplay between tumors and the immune system, with Robert D. Schreiber and Philip D. Greenberg serving as the Editors-in-Chief.

Table of Contents

What We're Reading

In the Spotlight

Research Articles

How chronic stress impacts glioma progression is unclear. The authors show it inhibits CCL3 secretion, exacerbating formation of an immunosuppressive microenvironment and thereby promoting glioma progression. CCL3 administration may be a new immunotherapy for glioma patients with depression.

Genome-wide identification of antigens targeted by individual TCRs can be challenging. The authors developed a new platform (Tsyn-seq) that allows for traditional cDNA library–based screening of antigen targets but is adapted for both increased ease and throughput.

PDAC is largely refractory to immunotherapy. The authors use machine learning models to disentangle the complex PDAC TME, revealing effector T cells are increased after neoadjuvant anti-CD40 immunotherapy, including in immune aggregate sites that correspond with improved DFS.

Sip-T is FDA approved to treat mCRPC. Using CyTOF, the authors show a lymphoid predominance in sip-T and provide evidence that IL15 treatment enhances sip-T antitumor function, providing rationale for combining IL15 or IL15 agonists with sip-T.

The authors uncover a central role for PVRL2 in suppressing antitumor immune responses, largely independent of its receptor PVRIG. Combined PVRL2 and TIGIT targeting results in a near-complete block in tumor growth, suggesting a novel therapeutic approach.

ILT2 and ILT4 play a role myeloid-cell inhibition in the tumor microenvironment. The authors show that combined blockade of ILT2 and ILT4 is required to induce optimal myeloid-cell reprogramming and activation in a solid tumor microenvironment.

The mechanisms by which TAM-derived exosomes influence tumor progression remain unclear. The authors show that ANXA3 promotes M2-like polarization of macrophages and ANXA3-rich exosomes secreted by TAMs regulate ferroptosis and lymphatic metastasis in LSCC.

The effects of CAR T-cell therapy on solid tumors remain limited. The authors show that treatment with a TOPK-specific inhibitor enhances GPC3-targeted CAR T-cell therapy in HCC tumor models by increasing central memory CD8+ CAR T cells.

Close Modal

or Create an Account

Close Modal
Close Modal